Advanced

Gastrointestinal stromal tumor - A review of clinical studies

Khoshnood, Ardavan LU (2019) In Journal of oncology pharmacy practice 25(6). p.1473-1485
Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging... (More)

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging results.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Oncology, GIST, gastrointestinal stromal tumor
in
Journal of oncology pharmacy practice
volume
25
issue
6
pages
1473 - 1485
publisher
SAGE Publications
external identifiers
  • scopus:85065644720
  • pmid:31068088
ISSN
1078-1552
DOI
10.1177/1078155219846955
language
English
LU publication?
yes
id
5d76917f-c4a6-4d47-a5ac-a6f9a5024676
date added to LUP
2019-05-13 09:33:44
date last changed
2020-07-08 04:50:59
@article{5d76917f-c4a6-4d47-a5ac-a6f9a5024676,
  abstract     = {<p>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging results.</p>},
  author       = {Khoshnood, Ardavan},
  issn         = {1078-1552},
  language     = {eng},
  month        = {05},
  number       = {6},
  pages        = {1473--1485},
  publisher    = {SAGE Publications},
  series       = {Journal of oncology pharmacy practice},
  title        = {Gastrointestinal stromal tumor - A review of clinical studies},
  url          = {http://dx.doi.org/10.1177/1078155219846955},
  doi          = {10.1177/1078155219846955},
  volume       = {25},
  year         = {2019},
}